41st week of 2020 patent applcation highlights part 31 |
Patent application number | Title | Published |
20200318097 | METHOD FOR PURIFYING RNA - The present invention relates to methods for purifying RNA by chromatography under high salt conditions, e.g. by hydrophobic interaction chromatography. | 2020-10-08 |
20200318098 | METHODS AND APPARATUS FOR FILTRATION - The invention features methods and apparatus for concentrating a nucleic acid. Methods of the invention include providing an initial suspension of a nucleic acid and an initial liquid, contacting the initial suspension with a housing having a filter that does not pass the nucleic acid, pressurizing the housing to produce a filtrate and a nucleic acid retentate from the initial solution, and detecting the volume of the nucleic acid retentate. Apparatus of the invention include a chamber configured to hold a filter housing containing a nucleic acid suspension, a pressure source to filter the suspension, and a detector to depressurize the housing upon detecting the volume reaching a predetermined threshold. The methods and apparatus described herein are useful in filtering, concentrating, and reconstituting nucleic acids, such as mRNA, in processes such as complete buffer replacement. | 2020-10-08 |
20200318099 | POLYPEPTIDE DISPLAY LIBRARIES AND METHODS OF MAKING AND USING THEREOF - Disclosed herein are expression vectors which display a passenger polypeptide on the outer surface of a biological entity. As disclosed herein the displayed passenger polypeptide is capable of interacting or binding with a given ligand. Also disclosed are methods of making and using the expression vectors. N/C terminal fusion expression vectors and methods of making and using are also disclosed. | 2020-10-08 |
20200318100 | AN ANTIBODY FRAGMENT LIBRARY, AND USES THEREOF - The present disclosure discloses an antibody fragment library, method for preparing the library and its applications. The essential steps in construction of the library is devoid of any restriction enzyme. Emulsion based PCR has been used as an important tool for the construction and validation of the library. The method as disclosed in the present disclosure leads to construction of a library comprising at least 8 billion clones. | 2020-10-08 |
20200318101 | METHODS OF SELECTING BINDING REAGENTS - Methods and systems are provided herein for selecting an affinity reagent which binds a desired peptide epitope in a plurality of sequence contexts. The method relies on obtaining a peptide library, each peptide having the sequence αXβ, wherein X is the desired peptide epitope, wherein each of a and 13 comprise an amino acid, using the peptide library to select an affinity reagent. | 2020-10-08 |
20200318102 | COMPOSITIONS AND METHODS FOR REPRESENTATIONAL SELECTION OF NUCLEIC ACIDS FROM COMPLEX MIXTURES USING HYBRIDIZATION - The invention provides a method of selecting a representational sample of nucleic acid sequences from a complex mixture. The method includes: (a) contacting a complex mixture of nucleic acids under conditions sufficient for hybridization with a population of capture probes complementary to one or more nucleic acids comprising a predetermined portion of the sequence collectively present in the complex mixture to form hybridization complexes of the one or more nucleic acids with the population of probes, the population of capture probes being attached to a solid support, and (b) removing unhybridized nucleic acids to select a representational sample of nucleic acids having a complexity of less than 10% but more than 0.001% of the complex mixture, wherein the representational sample comprises a nucleic acid copy having a proportion of each sequence in the copy relative to all other sequences in the copy substantially the same as the proportions of the sequences in the predetermined portion of one or more nucleic acids within the complex mixture. A method of selecting a representational sample of genomic sequences from a complete genome also is provided. The invention further provides a nucleic acid population that includes a representational sample having a complexity of less than 10% but more than 0.001% of a complex mixture, the representational sample comprising a nucleic acid copy having a proportion of each sequence in the copy relative to all other sequences in the copy substantially the same as the proportions of sequences in a predetermined portion of a sequence collectively present in one or more nucleic acids within the complex mixture. | 2020-10-08 |
20200318103 | STEREODEFINED SUB-MOTIF OPTIMISATION METHODS - The present invention relates to methods for identifying improved stereodefined phosphorothioate oligonucleotide variants of antisense oligonucleotides utilising sub-libraries of partially stereodefined oligonucleotides. The methods allow for the efficient identification of stereodefined variants with improved properties, such as enhanced in vitro or in vivo activity, enhanced efficacy, enhanced specific activity, reduced toxicity, altered biodistribution, enhanced cellular or tissue uptake, and/or enhanced target specificity (reduced off-target effects). | 2020-10-08 |
20200318104 | Micro-screening Apparatus, Process, and Products - Microcavity arrays and methods for quantitative biochemical and biophysical analysis of populations of biological variants. Examples include high-throughput analysis of cells and protein products use a range of fluorescent assays, including binding-affinity measurement and time-resolved enzyme assays. Laser-based extraction of microcavity contents. | 2020-10-08 |
20200318105 | CAR-T CELL ASSAY FOR SPECIFICITY TEST OF NOVEL ANTIGEN BINDING MOIETIES - The present invention generally relates to specificity assays using cell cultures, in particular to chimeric antigen receptor (CAR) expressing reporter T (CAR-T cell) assays to test antigen binding moieties in different formats. Furthermore, the present invention relates to the use of CAR-T cells, transfected/transduced with an engineered chimeric antigen receptor (CAR) comprising a target antigen binding moiety capable of specific binding to a target antigen, e.g., tumor associated antigens. | 2020-10-08 |
20200318106 | CONTROLLING PHENOTYPE OF ORGANISMS WITH CRISPR/CAS GENE TARGETING - Engineered microbial organisms for altering gene expression are provided. In some embodiments, the engineered microbial organism comprises: one or more heterologous polynucleotide sequence comprising a phenotype coding sequence operably linked to a promoter; a heterologous polynucleotide sequence comprising an inducible promoter operably linked to a polynucleotide encoding a Cas nuclease; and a heterologous polynucleotide sequence comprising a guide RNA (gRNA) that targets the phenotype coding sequence. | 2020-10-08 |
20200318107 | TRANSPOSITION OF NUCLEIC ACIDS INTO EUKARYOTIC GENOMES WITH A TRANSPOSASE FROM HELIOTHIS - The present invention provides polynucleotide vectors for high expression of heterologous genes. Some vectors further comprise novel transposons and transposases that further improve expression. Further disclosed are vectors that can be used in a gene transfer system for stably introducing nucleic acids into the DNA of a cell. The gene transfer systems can be used in methods, for example, gene expression, bioprocessing, gene therapy, insertional mutagenesis, or gene discovery. | 2020-10-08 |
20200318108 | MATERIALS AND METHODS FOR TREATMENT OF USHER SYNDROME TYPE 2A AND/OR NON-SYNDROMIC AUTOSOMAL RECESSIVE RETINITIS PIGMENTOSA (ARRP) - The present application provides materials and methods for treating a patient with one or more of Usher Syndrome Type 2A and ARRP, both ex vivo and in vivo; materials and methods for editing an USH2A gene containing a guanine deletion at nucleotide position c.2299. In addition, the present application provides one or more gRNAs or sgRNAs for editing an USH2A gene containing a guanine deletion at nucleotide position c.2299; a therapeutic comprising at least one or more gRNAs or sgRNAs for editing an USH2A gene containing a guanine deletion at nucleotide position c.2299; and a therapeutic for treating a patient with one or more of Usher Syndrome Type 2A and ARRP. The present application also provides a kit for treating a patient with one or more of Usher Syndrome Type 2A and ARRP. | 2020-10-08 |
20200318109 | LNA-G Process - Recent advancements in LNA oligonucleotides include the use of amine linkers to link an LNA antisense oligonucleotide to a conjugate group. For example please see WO2014/I 18267. The present invention originates from the identification of a problem when de-protecting LNA oligonucleotides which comprise an aliphatic amine group and DMF protected LNA G nucleoside, which results in the production of a +28 Da impurity. This problem is solved by using acyl protection groups on the exocyclic nitrogen of the LNA-G residue, rather than the standard DMF protection group. | 2020-10-08 |
20200318110 | A COMPOSITION AND METHOD OF USING MIR-302 PRECURSORS AS ANTI-CANCER DRUGS FOR TREATING HUMAN LUNG CANCER - This invention generally relates to a composition and method of using man-made small RNAs, such as small interfering RNAs (siRNA), microRNAs (miRNA) and their hairpin-like precursors (pre-miRNA), as tumor suppressing anti-cancer drugs for treating human tumors and cancers, in particular, but not limited, for treating skin (melanoma), blood (leukemia), prostate, breast, liver and lung cancers as well as various neoplastic tumors, such as brain tumors and teratocarcinomas that contain a variety of tumorous and cancerous cells derived from all three germ layers of tissues, including ectoderm, mesoderm and endoderm. More specifically, the present invention relates to the use of miR-302-like siRNA (siR-302) and/or miR-302 precursors (pre-miR-302) for developing novel medicines and therapies against a variety of human cancers, in particular lung cancers. | 2020-10-08 |
20200318111 | RNAI AGENTS, COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING TRANSTHYRETIN (TTR) ASSOCIATED DISEASES - The present invention provides RNAi agents, e.g., double stranded RNAi agents, that target the transthyretin (TTR) gene and methods of using such RNAi agents for treating or preventing TTR-associated diseases. | 2020-10-08 |
20200318112 | CANCER TREATMENT - In certain embodiments, methods, compounds, and compositions for treating B-cell lymphoma or hepatocellular carcinoma by inhibiting expression of STAT3 mRNA or protein in an animal are provided herein. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate B-cell lymphoma or hepatocellular carcinoma. | 2020-10-08 |
20200318113 | POLYNUCLEOTIDE CONJUGATES AND USES THEREOF - Provided herein are polynucleotide conjugates comprising a polynucleotide and an agent, wherein the polynucleotide comprises a synthetic double stranded miR-29 mimic and the agent facilitates the delivery of the polynucleotide to a cell type or tissue type involved in fibrosis or inflammation. Also provided are methods of making, and uses thereof. | 2020-10-08 |
20200318114 | C/EBP ALPHA SHORT ACTIVATING RNA COMPOSITIONS AND METHODS OF USE - The invention relates to saRNA targeting a C/EBPα transcript and therapeutic compositions comprising said saRNA. Methods of using the therapeutic compositions are also provided. | 2020-10-08 |
20200318115 | GENE THERAPIES FOR LYSOSOMAL DISORDERS - The disclosure relates, in some aspects, to compositions and methods for treatment of diseases associated with aberrant lysosomal function, for example Parkinson's disease and Gaucher disease. In some embodiments, the disclosure provides expression constructs comprising a transgene encoding one or more inhibitory nucleic acids targeting SCNA or a portion thereof, TMEM106B or a portion thereof, or any combination of the foregoing. In some embodiments, the disclosure provides methods of Parkinson's disease by administering such expression constructs to a subject in need thereof. | 2020-10-08 |
20200318116 | COMPOSITIONS AND THEIR USES DIRECTED TO HUNTINGTIN - Disclosed herein are compounds, compositions and methods for modulating the expression of huntingtin in a cell, tissue or animal. Further provided are methods of slowing or preventing Huntington's Disease (HD) progression using an antisense compound targeted to huntingtin. Additionally provided are methods of delaying or preventing the onset of Huntington's Disease (HD) in an individual susceptible to Huntington's Disease (HD). Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders. | 2020-10-08 |
20200318117 | Influenza-Activated Constructs and Methods of Use Thereof - The presently disclosed subject matter provides a novel approach for the treatment, prevention, and diagnosis of Cap-Snatching virus infections, particularly all classes of human influenza, including pandemic influenza. The methods involve the use of constructs for RNA-interference (RNAi). | 2020-10-08 |
20200318118 | METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF KRAS BY ASYMMETRIC DOUBLE-STRANDED RNA - This invention relates to compounds, compositions, and methods useful for reducing KRAS target RNA and protein levels via use of Dicer substrate siRNA (DsiRNA) agents possessing asymmetric end structures. | 2020-10-08 |
20200318119 | Compositions and Methods for Inhibiting Expression of the PCSK9 Gene - The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the PCSK9 gene (PCSK9 gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the PCSK9 gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier and method for treating diseases caused by PCSK9 gene expression. | 2020-10-08 |
20200318120 | Recombinant Protein - A recombinant protein comprising a functional polypeptide and, linked to the N-terminus of said functional polypeptide, an N-terminal spacer having a length such that the number of amino acid residues between a signal peptide cleaving site and an N-terminus proximal structural unit of said functional polypeptide is 14-24. | 2020-10-08 |
20200318121 | INTEGRATION OF NUCLEIC ACID CONSTRUCTS INTO EUKARYOTIC CELLS WITH A TRANSPOSASE FROM ORYZIAS - The present invention provides polynucleotide vectors for high expression of heterologous genes. Some vectors further comprise novel transposons and transposases that further improve expression. Further disclosed are vectors that can be used in a gene transfer system for stably introducing nucleic acids into the DNA of a cell. The gene transfer systems can be used in methods, for example, gene expression, bioprocessing, gene therapy, insertional mutagenesis, or gene discovery | 2020-10-08 |
20200318122 | UNNATURAL BASE PAIR COMPOSITIONS AND METHODS OF USE - Disclosed herein are methods, cells, engineered microorganisms, and kits for increasing the production of polypeptides comprising one or more unnatural amino acids. Further provided are cells, engineered microorganisms, and kits for increasing the retention of unnatural nucleic acids encoding the unnatural amino acids in an engineered cell, or semi-synthetic organism. | 2020-10-08 |
20200318123 | CRISPR-CAS COMPONENT SYSTEMS, METHODS AND COMPOSITIONS FOR SEQUENCE MANIPULATION - The invention provides for systems, methods, and compositions for manipulation of sequences and/or activities of target sequences. Provided are vectors and vector systems, some of which encode one or more components of a CRISPR complex, as well as methods for the design and use of such vectors. Also provided are methods of directing CRISPR complex formation in eukaryotic cells and methods for selecting specific cells by introducing precise mutations utilizing the CRISPR/Cas system. | 2020-10-08 |
20200318124 | REGULATORY ELEMENTS FROM LABYRINTHULOMYCETES MICROORGANISMS - The present disclosure generally relates to novel polynucleotide molecules for use in regulating gene expression in recombinant cells, such as labyrinthulomycetes cells. The disclosure further relates to nucleic acid constructs, such as vectors and expression cassettes, containing a regulatory element operably linked to a heterologous nucleotide sequence. The disclosure further relates to methods for stably transforming a host cell, such as a labyrinthulomycetes cell with transgenes. Stably transformed recombinant cells, progeny, biomaterials derived therefrom, and methods for preparing and using the same are also provided. | 2020-10-08 |
20200318125 | METHOD FOR INTRODUCING PROTEIN INTO PLANT CELL - It is an object of the present invention to provide a method for introducing a protein into a plant, which is simple and extensively applicable to various types of plant cells and proteins. The above object is achieved by the present invention to provide a complex comprising a protein of interest to be introduced into a target plant cell and a carrier peptide, a method for introducing a protein of interest into a target plant cell using the complex, and a kit comprising a protein of interest to be introduced into a target plant cell and a carrier peptide. | 2020-10-08 |
20200318126 | Multi-Pulse Transfection Methods And Cells - Systems and methods are provided for transfecting immune competent cells with RNA at high efficiency and viability. | 2020-10-08 |
20200318127 | PLANT PROMOTER FOR TRANSGENE EXPRESSION - This disclosure concerns compositions and methods for promoting transcription of a nucleotide sequence in a plant or plant cell, employing a promoter from a GmTEFs1 gene. Some embodiments relate to a promoter or a 5′ UTR from a GmTEFs1 gene that functions in plants to promote transcription of operably linked nucleotide sequences. Other embodiments relate to a 3′ UTR or a terminator from a GmTEFs1 gene that functions in plants to promote transcription of operably linked nucleotide sequences. | 2020-10-08 |
20200318128 | REGULATORY NUCLEIC ACID MOLECULES FOR ENHANCING CONSTITUTIVE GENE EXPRESSION IN PLANTS - The present invention is in the field of plant molecular biology and provides methods for production of high expressing constitutive promoters and the production of plants with enhanced constitutive expression of nucleic acids wherein nucleic acid expression enhancing nucleic acids (NEENAs) are functionally linked to the promoters and/or introduced into plants. | 2020-10-08 |
20200318129 | Compositions and Methods for Producing Tobacco Plants and Products Having Reduced or Eliminated Suckers - The present disclosure provides the identification of genes involved in sucker growth in tobacco. Also provided are promoters that are preferentially active in tobacco axillary buds. Also provided are modified tobacco plants comprising reduced or no sucker growth. Also provided are methods and compositions for producing modified tobacco plants comprising reduced or no sucker growth. | 2020-10-08 |
20200318130 | TRANSGENIC PLANTS WITH ENHANCED RESISTANCE TO ABIOTIC STRESS CONDITIONS - The present invention relates to a transgenic plant having increased tolerance to an abiotic stress, including freeze stress, cold stress, heat stress, salt stress, drought stress, osmotic stress, water stress, oxidative stress and/or ionic, wherein the transgenic plant is transformed with a nucleic acid sequence encoding a WHy protein comprising SEQ ID NO:2. The invention further relates to a method for obtaining a transgenic plant having increased tolerance to an abiotic stress, comprising transforming a plant with a nucleic acid sequence encoding the WHy protein. The present invention also relates to vegetative tissue from the transgenic plant of the invention or produced according to the method of the invention and to seeds containing a nucleic acid sequence encoding the WHy protein. | 2020-10-08 |
20200318131 | METHOD FOR MODIFYING THE RESISTANCE PROFILE OF SPINACIA OLERACEA TO DOWNY MILDEW - The present invention relates to a method for modifying the resistance profile of a spinach plant to | 2020-10-08 |
20200318132 | CHIMERIC INSECTICIDAL PROTEINS - IRDIG35563 vegetative insecticidal toxins, polynucleotides encoding such toxins, use of such toxins to control pests, and transgenic plants that produce such toxins are disclosed. The invention includes IRDIG35563 variants, fragments and analogs. | 2020-10-08 |
20200318133 | PESTICIDAL GENES AND METHODS OF USE - Compositions having pesticidal activity and methods for their use are provided. Compositions include isolated and recombinant polypeptides having pesticidal activity, recombinant and synthetic nucleic acid molecules encoding the polypeptides, DNA constructs and vectors comprising the nucleic acid molecules, host cells comprising the vectors, and antibodies to the polypeptides. Polynucleotide sequences encoding the polypeptides can be used in DNA constructs or expression cassettes for transformation and expression in organisms of interest. The compositions and methods provided are useful for producing organisms with enhanced pest resistance or tolerance. Transgenic plants and seeds comprising a nucleotide sequence that encodes a pesticidal protein of the invention are also provided. Such plants are resistant to insects and other pests. Methods are provided for producing the various polypeptides disclosed herein, and for using those polypeptides for controlling or killing a pest. Methods and kits for detecting polypeptides of the invention in a sample are also included. | 2020-10-08 |
20200318134 | METHODS FOR SCARLESS INTRODUCTION OF TARGETED MODIFICATIONS INTO TARGETING VECTORS - Methods for introducing a scarless targeted genetic modification into a preexisting targeting vector are provided. The methods can use combinations of bacterial homologous recombination (BHR) and in vitro assembly to introduce such targeted genetic modifications into a preexisting targeting vector in a scarless manner. | 2020-10-08 |
20200318135 | TRANSPOSITION OF NUCLEIC ACID CONSTRUCTS INTO EUKARYOTIC GENOMES WITH A TRANSPOSASE FROM AMYELOIS - The present invention provides polynucleotide vectors for high expression of heterologous genes. Some vectors further comprise novel transposons and transposases that further improve expression. Further disclosed are vectors that can be used in a gene transfer system for stably introducing nucleic acids into the DNA of a cell. The gene transfer systems can be used in methods, for example, gene expression, bioprocessing, gene therapy, insertional mutagenesis, or gene discovery. | 2020-10-08 |
20200318136 | METHODS AND COMPOSITIONS FOR INSERTION OF ANTIBODY CODING SEQUENCES INTO A SAFE HARBOR LOCUS - Methods and compositions are provided for integrating coding sequences for antigen-binding proteins such as broadly neutralizing antibodies into a safe harbor locus such as an albumin locus in an animal in vivo. | 2020-10-08 |
20200318137 | TRAIL-SECRETING MESENCHYMAL STEM CELLS AND USE THEREOF TO TREAT BRAIN TUMORS - The invention relates to the field of genetic recombination and stein cell application. In particular, the invention provides a construct for expressing a soluble fragment of a secretory TRAIL, and a lentiviral expression vector comprising the construct. The present invention also provides a mesenchymal stein cell in which the construct is integrated into the genome, which can express and secrete the TRAIL fragment. The invention also provides the use of the construct or vector or mesenchymal stein cells for the treatment of brain tumors. | 2020-10-08 |
20200318138 | CONSTRUCTS COMPRISING NEURONAL VIABILITY FACTORS AND USES THEREOF - The present invention relates to improved constructs comprising the short and long Rod-Derived Cone Viability Factors and to methods for treating retinal degenerative diseases. | 2020-10-08 |
20200318139 | GENOME ENGINEERING WITH TYPE I CRISPR SYSTEMS IN EUKARYOTIC CELLS - Disclosed herein are Type I Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated (Cas) system related compositions and methods of using said Type I CRISPR/Cas system related compositions for altering gene expression and genome engineering. The invention relates to compositions comprising Type I CRISPR-Cas polypeptides and CRISPR array nucleic acids designed for genome modification in eukaryotic cells and for targeted killing of eukaryotic cells. | 2020-10-08 |
20200318140 | METHODS AND COMPOSITIONS FOR INCREASING RNA ACTIVITY IN A CELL - Disclosed herein are methods and compositions for increasing RNA activity in a cell. | 2020-10-08 |
20200318141 | BIOSLURRY-INDUCED WATER BARRIER AND PROCESS OF FORMING THEREOF - Disclosed herein is a process of forming an inorganic water barrier layer on top of a porous substrate by means of microbially induced calcium carbonate or calcite precipitation (MICP), the process comprising the steps of: providing a porous substrate having a surface; depositing a urease-active slurry onto the surface of the porous substrate to form a bioslurry layer; and subjecting the bioslurry layer to one or more treatments with an aqueous solution comprising urea and a water barrier source material to convert the bioslurry layer into an inorganic water barrier layer. The process further comprises a step of covering the bioslurry layer with a layer of a porous material that has a surface, where the one or more treatments with an aqueous solution comprising urea and a water barrier source material are initially applied to the surface of the porous material. The porous material acts as a reservoir for the aqueous solution to sustain the biocementation of bioslurry into the desired inorganic water barrier layer. | 2020-10-08 |
20200318142 | ALGAL BIOFUEL PRODUCTION AS AN AIR SEPARATION UNIT FOR SYNGAS, HYDROGEN, OR POWER PRODUCTION - This invention relates to methods and apparatus for harvesting by-product oxygen from algae ponds or bioreactors (collectively, “algal biofuel production”) for use in an oxygen-requiring process that requires oxygen as a reactant such as syngas, hydrogen, or power production processes, which optionally can be integrated with the algal biofuel production. In some embodiments, the invention provides methods that include a method comprising: collecting oxygen from an algal biofuel production process; and using the collected oxygen in an oxygen-requiring process that requires oxygen as a reactant. In some embodiments, the invention provides systems that include an integrated system comprising: an algal bioreactor that produces biodiesel and oxygen, a pipeline for transporting oxygen to an oxygen-requiring process unit so that the oxygen can be used as reactant in the oxygen-requiring process unit, and the oxygen-requiring process unit. | 2020-10-08 |
20200318143 | PRETREATMENT METHOD FOR PRODUCING LYCOPENE RAW MATERIAL - A pretreatment method for producing a raw material of lycopene, comprising: uniformly mixing tomato peel residue with a fermenting agent, an antioxidant and an enzyme preparation, and subjecting the resultant to light-proof anaerobic fermentation. The present invention employs bacteria-enzyme combined fermentation technology, which prolongs the storage period of wet tomato peel residue, and also destroys the cell wall of tomato peels, thus facilitating exaction of lycopene and improving the purity of lycopene extracted in the later stage. | 2020-10-08 |
20200318144 | METHOD AND DEVICE FOR STIMULATING BIOLOGICAL FERMENTATION - Disclosures of the present invention describe a method and device for stimulating biological fermentation. In the present invention, a light source is particularly used for stimulating a biological fermentation by supplying an illumination light with a color temperature in a range between 1600K and 4300K. Moreover, a variety of experimental data have proved that, the illumination light is indeed helpful in stimulating the biological fermentation occurring in an object under fermentation so as to enhance a rate of ethanol fermentation. It is worth further explaining that, the method and the device for stimulating biological fermentation can be applied in any one type of fermentation apparatus. | 2020-10-08 |
20200318145 | CONTINUOUS ETHANOL RECOVERY FROM FERMENTATION WITH HIGH SOLIDS CORN SLURRY PRODUCTION - A system and method for continuous ethanol recovery from high solids corn slurry mash fermentation in an ethanol plant. | 2020-10-08 |
20200318146 | METABOLIC ENGINEERING FOR SIMULTANEOUS CONSUMPTION OF XYLOSE AND GLUCOSE FOR PRODUCTION OF CHEMICALS FROM SECOND GENERATION SUGARS - The present disclosure provides methods for genetically modifying microbes to produce a microbe capable of simultaneous consumption of xylose and glucose to increase the productivity output of desired chemical products. The disclosure further provides modified bacteria that are capable of simultaneous consumption of xylose and glucose, and compositions comprising the microbes. | 2020-10-08 |
20200318147 | TRANSFORMED FUNGUS HAVING ENHANCED ERGOTHIONEINE PRODUCTIVITY AND METHOD FOR PRODUCING ERGOTHIONEINE - The purpose of the present invention is to provide an organism having an ergothioneine productivity that is capable of easily producing ergothioneine within a short period of time at a high yield, as compared with a conventional technology, and, therefore, enables ergothioneine production on an industrial scale. This purpose can be achieved by a transformed fungus into which a gene encoding enzyme (1) or genes encoding enzymes (1) and (2) have been inserted and in which the inserted gene(s) are overexpressed. (1) an enzyme catalyzing a reaction of synthesizing hercynyl cysteine sulfoxide from histidine and cysteine in the presence of S-adenosyl methionine, iron (II) and oxygen. (2) An enzyme catalyzing a reaction of synthesizing ergothioneine from hercynyl cysteine sulfoxide using pyridoxal 5′-phosphate as a coenzyme. | 2020-10-08 |
20200318148 | SYNTHETIC BIOLOGICAL CIRCUITS FOR THE DETECTION OF TARGET ANALYTES USING A GLUCOSE METER IN A CELL-FREE SYSTEM - Described are methods for generating a reporter molecule in response to a target analyte in a cell-free system. A synthetic biological circuit is used to modify the level of the reporter molecule in response to the presence of the target analyte. The reporter molecule may be glucose or another molecule readily detected using a device such as glucose monitor or other portable sensor. Also provided are kits comprising a cell-free system with a synthetic biological circuit that generates or consumes a reporter molecule in response to a target analyte. | 2020-10-08 |
20200318149 | SEED TRAIN FOR LARGE SCALE ENZYME PRODUCTION - The invention relates to an optimized seed train expansion process. | 2020-10-08 |
20200318150 | Methods and Compositions for Improved Expression of Recombinant Proteins - Provided herein are methods for the improved production of periplasmic-targeted recombinant proteins in | 2020-10-08 |
20200318151 | METHOD FOR PRODUCING MICROBIAL PROBIOTIC BIOFILMS AND USES THEREOF - The present invention relates to a method for producing microbial probiotic biofilms and their uses in the biomedical, industrial, food and environmental field. | 2020-10-08 |
20200318152 | UREA BIOSENSORS AND STABILIZATION OF UREA BIOSENSORS AT ROOM TEMPERATURE - Disclosed is a urea biosensor that is stable at ambient temperature, and methods of making thereof. | 2020-10-08 |
20200318153 | Method and device of using aqueous two-phase systems (ATPS) for enhancing diagnostics for dental and oral diseases - This invention relates to a method and device to improve the detection accuracy and performance for diagnosing dental disorders or diseases by improving the sensitivity of the Lateral-Flow Immunoassay (LFA). The present method and device are related to removing the protein interference (impurities) from sample and using aqueous two-phase system (ATPS) embedded entirely within a porous material, allowing spontaneous phase separation and concentration, for detection using the Lateral-Flow Immunoassay (LFA). The present invention also provides a platform technology for screening different types of specimens with increased sensitivity, and screening antibodies for optimal detection in various types of samples. | 2020-10-08 |
20200318154 | Random Heteropolymers Preserve Protein Function in Foreign Environments - Compositions comprise statistically random heteropolymers complexed with active proteins, and are formulated and used in stimuli-responsive materials and nanoreactors composed of proteins and synthetic materials. | 2020-10-08 |
20200318155 | METHOD AND REAGENT FOR QUANTIFYING CHOLESTEROL IN TRIGLYCERIDE-RICH LIPOPROTEIN - Disclosed are a method and reagent of quantifying cholesterol in triglyceride-rich lipoprotein (TRL-C) in a test sample in a more specific manner without requiring laborious operations. The method of quantifying cholesterol in triglyceride-rich lipoprotein (TRL-C) includes the steps of: (1) selectively eliminating cholesterol in lipoproteins other than triglyceride-rich lipoprotein (TRL) by allowing a cholesterol esterase having a molecular weight of more than 50 kDa and a surfactant(s) to act; and (2) quantifying the remaining TRL-C. | 2020-10-08 |
20200318156 | QUANTITATIVE ASSESSMENT FOR CAP EFFICIENCY OF MESSENGER RNA - The present invention provides, among other things, methods of quantitating mRNA capping efficiency, particularly mRNA synthesized in vitro. In some embodiments, methods according to the present invention comprise providing an mRNA sample containing capped and uncapped mRNA, providing a cap specific binding substance under conditions that permit the formation of a complex between the cap specific binding substance and the capped mRNA, and quantitatively determining the amount of the complex as compared to a control, thereby quantifying mRNA capping efficiency. | 2020-10-08 |
20200318157 | DIGITAL ANALYTE ANALYSIS - The invention generally relates to droplet based digital PCR and methods for analyzing a target nucleic acid using the same. In certain embodiments, a method for determining the nucleic acid make-up of a sample is provided. | 2020-10-08 |
20200318158 | REACTION VESSEL SYSTEMS AND METHODS AND SYSTEMS FOR USING SAME - Aspects of the present disclosure include systems that include reaction vessels and reaction vessel caps. In certain aspects, the reaction vessels include a reaction chamber and a groove disposed around a top opening of a reaction chamber. The system also includes a RV cap that includes a cap body, a RV plug, and a lower wall that includes an outer radial groove disposed above an outward projecting ridge of the lower wall. When the cap is inserted into the RV, the RV plug of the RV cap is sealingly inserted into the reaction chamber of the RV, a ridge of the RV mates with the outer radial groove of the RV cap, and an outward projecting ridge of the RV cap mates with the radial groove of the RV. Also provided are methods and sample analysis systems, which may employ the RV/RV cap systems of the present disclosure. | 2020-10-08 |
20200318159 | REAGENTS AND METHODS FOR BLOCKING NON-SPECIFIC INTERACTIONS WITH NUCLEIC ACIDS - Methods and reagents for blocking non-specific interactions with nucleic acids are disclosed. In particular, the invention relates to multi-valent blockers comprising multiple negatively charged polymers or materials attached to a common scaffold and their use in blocking non-specific interactions with nucleic acids. | 2020-10-08 |
20200318160 | Sample to Sequence - Method and sample vessels are provided for amplification and sequencing of nucleic acids in a sample. | 2020-10-08 |
20200318161 | PRESERVATION OF CELL-FREE NUCLEIC ACIDS - A method for preserving and processing cell-free nucleic acids located within a blood sample is disclosed, wherein a blood sample containing cell-free nucleic acids is treated to reduce both blood cell lysis and nuclease activity within the blood sample. The treatment of the sample aids in increasing the amount of cell-free nucleic acids that can be identified and tested while maintaining the structure and integrity of the nucleic acids. | 2020-10-08 |
20200318162 | GUT BACTERIA IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE AND METHODS THEREWITH IN DETECTING ILEAL FIBROSIS - The present invention describes methods of identifying subjects susceptible to fibrosis by targeting bacteria found in intestine-related adipose tissue such as creeping fat, ileal mucosa or related tissue. Based on subject's susceptibility to developing fibrosis, different intervention or treatment options can be used. | 2020-10-08 |
20200318163 | BIODEGRADATION OF TOXIC ORGANIC COMPOUNDS IN CONTAMINATED ENVIRONMENTS - The present disclosure relates generally to methods and/or means for generating and analyzing gene expression profiles of a microorganism isolated from an environment contaminated with toxic organic compounds. In particular, the disclosure relates to methods and/or means of identifying genes, enzymes, and metabolic pathways involved in naphthenic acids compounds (NAFC) or naphthenic acid (NA) degradation activity. Engineered microorganisms with increased naphthenic acid (NA) degradation activity and their use for biodegradation of toxic organic compounds in contaminated environments are further provided. | 2020-10-08 |
20200318164 | METHOD FOR DETECTING AND CHARACTERISING A MICROORGANISM - A method for detecting and characterizing a microorganism in a clinical sample includes introducing a clinical sample to a first culture vessel containing the culture medium; removing a test aliquot; separating DNA from the test aliquot; and performing nucleic acid tests on the DNA to identify the microorganism and to detect the presence or absence of one or more genetic antimicrobial resistance markers in the microorganism. If a microorganism is identified, an antimicrobial susceptibility test is performed wherein microbial growth in the antimicrobial susceptibility test is monitored by accessing growth or markers for growth and wherein the type and concentration of antimicrobial agents used in the antimicrobial susceptibility test is determined by the identity of the microorganism and the antimicrobial resistance markers detected. A device for performing the method is also provided. | 2020-10-08 |
20200318165 | Rapid Identification of Microorganisms - Methods of labeling, identifying and differentiating microorganisms using functionalized Buckyballs are provided herein. The invention further provides methods for imaging or inhibiting gene expression using functionalized Buckyballs of the invention. The invention also provides a system for labeling, identifying and differentiating microorganisms. | 2020-10-08 |
20200318166 | Multiplexed Screening - Methods and apparatus to test and screen compounds in a multiplexed manner, using a mixture of genetically or functionally heterogeneous cells in common conditions. | 2020-10-08 |
20200318167 | COMPOSITIONS, SYSTEMS, AND METHODS FOR DETECTING THE PRESENCE OF POLYMER SUBUNITS USING CHEMILUMINESCENCE - Under one aspect, a composition includes a substrate; a first polynucleotide coupled to the substrate; a second polynucleotide hybridized to the first polynucleotide; and a catalyst coupled to a first nucleotide of the second polynucleotide, the catalyst being operable to cause a chemiluminogenic molecule to emit a photon. Under another aspect, a method includes providing a catalyst operable to cause a first chemiluminogenic molecule to emit a photon; providing a substrate; providing a first polynucleotide coupled to the substrate; hybridizing a second polynucleotide to the first polynucleotide; coupling a first quencher to a first nucleotide of the second polynucleotide; and inhibiting, by the first quencher, photon emission by the first chemiluminogenic molecule. | 2020-10-08 |
20200318168 | UPCONVERSION NANOPARTICLE-BASED MOLECULAR PROBES AND METHODS OF USE - Oligonucleotide probes and kits containing same are disclosed, along with methods of use thereof. The oligonucleotide probe comprises a nucleic acid probe sequence comprising a hairpin loop and having a reporter moiety linked to a first end thereof and a quencher moiety linked to a second end thereof. In certain embodiments, the reporter moiety is an upconversion nanoparticle, and the quencher moiety is a gold nanoparticle. The quencher moiety quenches the reporter moiety when the nucleic acid probe sequence is not bound to a complementary target nucleic acid sequence, and the reporter moiety becomes unquenched when the nucleic acid probe sequence binds to a complementary target nucleic acid sequence. | 2020-10-08 |
20200318169 | PRODUCTS AND PROCESSES FOR MULTIPLEX NUCLEIC ACID IDENTIFICATION - Provided herein are products and processes for detecting the presence or absence of multiple target nucleic acids. Certain methods include amplifying the target nucleic acids, or portion thereof; extending oligonucleotides that specifically hybridize to the amplicons, where the extended oligonucleotides include a capture agent; capturing the extended oligonucleotides to a solid phase via the capture agent; releasing the extended oligonucleotide by competition with a competitor; detecting the extended oligonucleotide, and thereby determining the presence or absence of each target nucleic acid by the presence or absence of the extended oligonucleotide. | 2020-10-08 |
20200318170 | METHODS AND SYSTEMS FOR NUCLEIC ACID SEQUENCING - The disclosure provides methods for sequencing nucleic acids using, including with nucleotide analogs and subsequently appended labels. | 2020-10-08 |
20200318171 | Compositions and Methods for Detecting Toxigenic Clostridium Difficile - Provided herein are compositions, kits, and methods for detecting at least one of a | 2020-10-08 |
20200318172 | NOVEL CRISPR ENZYMES AND SYSTEMS - The invention provides for systems, methods, and compositions for targeting nucleic acids. In particular, the invention provides non-naturally occurring or engineered DNA-targeting systems comprising a novel DNA-targeting CRISPR effector protein and at least one targeting nucleic acid component like a guide RNA. Methods for making and using and uses of such systems, methods, and compositions and products from such methods and uses are also disclosed and claimed. | 2020-10-08 |
20200318173 | NOVEL CRISPR ENZYMES AND SYSTEMS - The invention provides for systems, methods, and compositions for targeting nucleic acids. In particular, the invention provides non-naturally occurring or engineered DNA-targeting systems comprising a novel DNA-targeting CRISPR effector protein and at least one targeting nucleic acid component like a guide RNA. Methods for making and using and uses of such systems, methods, and compositions and products from such methods and uses are also disclosed and claimed. | 2020-10-08 |
20200318174 | COMPOSITIONS AND METHODS FOR IDENTIFYING AND CHARACTERIZING GENE TRANSLOCATIONS, REARRANGEMENTS AND INVERSIONS - In alternative embodiments, provided are methods comprising use of FISH, IHC or equivalent gene fusion detection protocols, and gene sequencing, wherein optionally the gene sequencing is high throughput or next generation gene sequencing, for the identification and characterization of gene abnormalities such as gene breakages; optionally gene breakages comprise gene translocation, gene rearrangements and/or gene inversions. In alternative embodiments, genes or transcripts are analyzed from individuals suspected of having cancer, and the analysis is carried out on biological samples taken from these individuals. This identification and characterization of gene abnormalities can be used in the diagnosis and treatment of a cancer. | 2020-10-08 |
20200318175 | METHODS FOR PARTNER AGNOSTIC GENE FUSION DETECTION - A method for detecting a gene fusion includes amplifying a nucleic acid sample in the presence of primer pool to produce a plurality of amplicons. The primer pool includes primers targeting a plurality of exon-exon junctions of a driver gene. The amplicons correspond to the exon-exon junctions. The amplicons are sequenced and aligned to a reference sequence. The number of reads corresponding to each amplicon is normalized to give a normalized read count. A baseline correction is applied to the normalized read counts for the amplicons to form corrected read counts. A binary segmentation score is calculated for each corrected read count. A predicted breakpoint for the gene fusion is determined based on the amplicon index corresponding to the maximum absolute binary segmentation score. Gene fusion events may be detected in a partner agnostic manner, i.e. without prior knowledge of the specific fusion partner genes or specific breakpoint information. | 2020-10-08 |
20200318176 | CONCENTRATION BASED DNA SEQUENCING MACHINE - The term DNA sequencing is commonly applied to several methods and technologies that are used for determining the order of the nucleotide bases adenine, guanine, cytosine, and thymine in a molecule of DNA. It has many applications in numerous applied fields such as diagnostic, biotechnology, forensic biology and biological systematic, in the sequencing of the human genome, and in the Human Genome Project. In the presented machine, DNA sample fragments are amplified by usual PCR technique. The individual nucleotides are added to the nascent DNA. If the nucleotide is complementary to the tested DNA fragment, a change in the concentration of the added nucleotide could be traced. This change could be detected by any method indicating a complementary nucleotide. Finally, the combined data are used to generate sequence read-outs by computer system. | 2020-10-08 |
20200318177 | NUCLEIC ACID SEQUENCING METHOD - The present invention provides a method for sequencing a nucleic acid using an immersion reaction protocol. The immersion reaction protocol comprises sequentially immersing a solid support having nucleic acid molecules immobilized thereon in different reaction containers to realize nucleic acid sequencing. | 2020-10-08 |
20200318178 | FRET-LABELED COMPOUNDS AND USES THEREFOR - FRET-labeled compounds are provided for use in analytical reactions. In certain embodiments, FRET-labeled nucleotide analogs are used in place of naturally occurring nucleoside triphosphates or other analogs in analytical reactions comprising nucleic acids, for example, template-directed nucleic acid synthesis, DNA sequencing, RNA sequencing, single-base identification, hybridization, binding assays, and other analytical reactions. | 2020-10-08 |
20200318179 | SAMPLE PREPARATION METHOD - The invention relates to an improved method for characterising a template polynucleotide. The method involves using a polymerase to prepare a modified polynucleotide which makes it easier to characterise than the template polynucleotide. | 2020-10-08 |
20200318180 | COMPOSITIONS, SYSTEMS, AND METHODS FOR SEQUENCING POLYNUCLEOTIDES USING TETHERS ANCHORED TO POLYMERASES ADJACENT TO NANOPORES - A composition includes a nanopore including first and second sides and an aperture, nucleotides each including an elongated tag, and a first polynucleotide that is complementary to a second polynucleotide. A polymerase can be disposed adjacent to the first side of the nanopore and configured to add nucleotides to the first polynucleotide based on a sequence of the second polynucleotide. A permanent tether can include a head region anchored to the polymerase, a tail region, and an elongated body disposed therebetween that occurs in the aperture of the nanopore. A first moiety can be disposed on the elongated body that binds to the elongated tag of a first nucleotide upon which the polymerase is acting. A reporter region can be disposed on the elongated body that indicates when the first nucleotide is complementary or is not complementary to a next nucleotide in the sequence of the second polynucleotide. | 2020-10-08 |
20200318181 | Method for obtaining single-cell mRNA sequence - Disclosed is a method for obtaining a single-cell mRNA sequence. The method of the present invention comprises: (1) capturing mRNA of a cell by using a cell tag carrier, and performing reverse transcription to obtain cDNA having a cell tag, cDNAs from the same cell having the same cell tag, and cDNAs from different cells having different cell tags; (2) obtaining multiple cDNA fragments having molecular tags by using a transposase complex and a molecular tag carrier, the fragments from the same cDNA having the same molecular tag, and the fragments from different cDNAs having different molecular tags; (3) performing high-throughput sequencing; (4) performing sequence assembly according to the molecular tags to obtain the sequence of each mRNA; and obtaining the sequence of all mRNAs of each single cell according to the cell tags. The method provided by the present invention can be used for obtaining the sequence of all mRNAs of each of a large number of single cells by means of high throughput. | 2020-10-08 |
20200318182 | METHODS AND ARRAYS FOR PRODUCING AND SEQUENCING MONOCLONAL CLUSTERS OF NUCLEIC ACID - The present disclosure relates to the field of molecular biology and more specifically to microarrays and methods. | 2020-10-08 |
20200318183 | METHODS FOR IDENTIFYING NUCLEOTIDES IN TARGET SEQUENCES - The present invention is directed to methods and compositions for acquiring nucleotide sequence information of target sequences. In particular, the present invention provides methods and compositions for improving the efficiency of sequencing reactions by using fewer labels to distinguish between nucleotides and by detecting nucleotides at multiple detection positions in a target sequence. | 2020-10-08 |
20200318184 | POLYNUCLEOTIDE PRIMERS AND PROBES - The present invention provides a novel technology that involves improved primer design. These primer pairs have a wide range of applications and provide high sensitivity and specificity. | 2020-10-08 |
20200318185 | METHODS OF LOWERING THE ERROR RATE OF MASSIVELY PARALLEL DNA SEQUENCING USING DUPLEX CONSENSUS SEQUENCING - Next Generation DNA sequencing promises to revolutionize clinical medicine and basic research. However, while this technology has the capacity to generate hundreds of billions of nucleotides of DNA sequence in a single experiment, the error rate of approximately 1% results in hundreds of millions of sequencing mistakes. These scattered errors can be tolerated in some applications but become extremely problematic when “deep sequencing” genetically heterogeneous mixtures, such as tumors or mixed microbial populations. To overcome limitations in sequencing accuracy, a method Duplex Consensus Sequencing (DCS) is provided. This approach greatly reduces errors by independently tagging and sequencing each of the two strands of a DNA duplex. As the two strands are complementary, true mutations are found at the same position in both strands. In contrast, PCR or sequencing errors will result in errors in only one strand. This method uniquely capitalizes on the redundant information stored in double-stranded DNA, thus overcoming technical limitations of prior methods utilizing data from only one of the two strands. | 2020-10-08 |
20200318186 | Nucleic Acid Probe and Method of Detecting Genomic Fragments - Provided herein, among other things, is a method of processing a nucleic acid sample. In some embodiments, the method comprises a) hybridizing a sample comprising a target fragment to a nucleic acid probe comprising: i. a head sequence and a tail sequence, wherein the head and tail sequences are at the ends of a first oligonucleotide molecule; and ii. a splint sequence comprising, in order: an upstream flanking sequence that is complementary to the head sequence; a target complementary sequence that is complementary to the target fragment; and a downstream flanking sequence that is complementary to the tail sequence; thereby producing a hybridization product in which the ends of the target fragment are ligatably adjacent to the ends of the head and tail sequences in the first oligonucleotide molecule; and b) ligating the ends of the target fragment to the ends of the head and tail sequences of the first oligonucleotide molecule, thereby producing a cyclic product that comprises the target fragment and the head and tail sequences. Probes and kits for performing the method are also provided. | 2020-10-08 |
20200318187 | QUANTITATIVE SCORE OF HLA DIVERSITY - Provided herein are systems and methods for quantitating the HLA diversity in a solid tissue or circulating tumor DNA sample that is predictive of a patient's responsiveness to immune checkpoint inhibitory therapies. | 2020-10-08 |
20200318188 | PRECISION MEDICINE FOR TREATING AND PREVENTING SUICIDALITY - The present disclosure relates generally to discovery of novel compounds involved in the treatment and prevention of suicidality by bioinformatics drug repurposing using novel genes expression biomarkers involved in suicidality. Disclosed are methods for assessing severity, determining future risk, matching with a drug treatment, and measuring response to treatment, for suicidality. Also disclosed are new methods of use for drugs and natural compounds repurposed for use in preventing and treating suicidality. These methods include computer-assisted methods analyzing the expression of panels of genes, clinical measures, and drug databases. Detailed herein are methods using a universal approach, in everybody, as well as personalized approaches by gender, and by diagnosis. The discovery describes compounds for use in everybody (universal), as well as personalized by gender (males, females), diagnosis (bipolar, depression), gender and diagnosis combined (male bipolar, male depression), male PTSD, male SZ/SZA), and subtypes of suicidality (high anxiety, low mood, combined (affective), and high psychosis (non-affective). Also disclosed are methods for identifying which subjects should be receiving which treatment, using genes expression biomarkers for patient stratification and measuring response to treatment. The disclosure also relates to algorithms, universal and personalized by gender and diagnosis. The algorithms combine biomarkers as well as clinical measures for suicidality and for mental state, in order to identify subjects who are at risk of committing suicide, as well as to track responses to treatments. The disclosure further relates to determining subtypes of suicidality. Such subtypes may delineate groups of individuals that are more homogenous in terms of biology, behavior, and response to treatment. | 2020-10-08 |
20200318189 | METHOD FOR ASSESSING THE RISK OF CUTANEOUS ADVERSE DRUG REACTIONS INDUCED BY ANTI-EPILEPTIC DRUG LAMOTRIGINE, DETECTION REAGENT THEREOF AND USE THEREOF - A method for assessing the risk of cutaneous adverse drug reactions induced by an anti-epileptic drug Lamotrigine is provided, wherein the cutaneous adverse drug reactions include but are not limited to: maculopapular eruption (MPE), fixed drug eruption (FDE), Stevens Johnson Syndrome (SJS), toxic epidermal necrolysis (TEN), drug rash with eosinophilia and systemic symptoms (DRESS). Further provided is a detection reagent for assessing the risk of a patient developing the cutaneous adverse drug reactions induced by the anti-epileptic drug Lamotrigine, comprising agents for measuring a particular HLA allele and the use thereof. | 2020-10-08 |
20200318190 | STRATIFICATION OF RISK OF VIRUS ASSOCIATED CANCERS - Provided herein are methods and systems for stratifying risk for a subject to develop a pathogen-associated disorder based on analysis of cell-free nucleic acid molecules from a biological sample of the subject. In various examples, screening frequency is determined based on the risk analysis. Also provided herein are methods and systems for analyzing variant patterns of a pathogen genome in cell-free nucleic acid molecules. | 2020-10-08 |
20200318191 | METHODS FOR SIMULTANEOUS AMPLIFICATION OF TARGET LOCI - The invention provides methods for simultaneously amplifying multiple nucleic acid regions of interest in one reaction volume as well as methods for selecting a library of primers for use in such amplification methods. The invention also provides library of primers with desirable characteristics, such as minimal formation of amplified primer dimers or other non-target amplicons. | 2020-10-08 |
20200318192 | METHODS, TOOLS AND SYSTEMS FOR THE ASSESSMENT, PREVENTION, MANAGEMENT AND TREATMENT SELECTION FOR TYPE 2 DIABETES - The present invention provides a method of assessing type 2 diabetes susceptibility and/or predicting treatment responsiveness in a human subject, the method comprising determining the identity of at least one allele at each of three or more positions of single nucleotide polymorphism (SNP) selected from the group consisting of: SLC16A11-rs75493593; HNF1A-rs483353044; TCF7L2-rs7903146; CDKN2A/B-rs10811661; CDKAL1-rs7756992; SLC30A8-rs3802177; IGF2BP2-rs4402960; FTO-rs9936385; PPARG-rs1801282; HHEX/IDE-rs1111875; ADCYS-rs11717195; JAZF1-rs849135; WSF1-rs4458523; INS-IGF2-rs149483638; KCNQ1-rs2237897; and KCNJ11-rs5219, and/or an SNP in linkage disequilibrium with any one of said SNPs at r | 2020-10-08 |
20200318193 | METHOD FOR DETERMINING DECREASE IN FUNCTIONS OF HIPPOCAMPUS BY USING CORRELATION BETWEEN MICRO RNA AND NMDA RECEPTOR, METHOD FOR INHIBITING DECREASE IN FUNCTIONS, AND METHOD FOR SCREENING FOR INHIBITORS OF DECREASE IN FUNCTIONS - The present invention relates to a method for determining a decrease in the functions of the hippocampus by using the correlation between a micro RNA (miRNA) and an N-methyl-D-aspartate receptor (NMDAR), a method for inhibiting the decrease in the functions, and a method for screening for inhibitors of the decrease in the functions. The present invention confirms that miR-204, among miRNAs up-regulated in an aged hippocampus, decreases the expression of EphB2, by accurately targeting EphB2, which is an important regulatory receptor, resulting in a decrease in the neuronal surface expression of an NR1 subunit of an NMDAR in hippocampal nerves and a decrease in the density of dendrites, thereby having an effect of determining whether the functions of the hippocampus are decreased, by using the correlation between a miRNA and an NMDAR, and furthermore, has an effect of providing a method for inhibiting the decrease in the functions of the hippocampus, and a method for screening for inhibitors of the decrease in the functions. | 2020-10-08 |
20200318194 | PERSONALIZED PAIN MANAGEMENT AND ANESTHESIA: PREEMPTIVE RISK IDENTIFICATION AND THERAPEUTIC DECISION SUPPORT - Methods and compositions disclosed herein generally relate to methods of improving clinical and economic outcomes to address adverse effects related to anesthesia, analgesics, opioids, and inadequate pain relief. Embodiments of the invention relate to the association between genes, specific polymorphisms of genes, and non-genetic factors with inadequate pain relief and anesthesia-, analgesic, and/or opioid-related adverse effects. Embodiments of the invention can be used to determine and manage patient risk factors for development of adverse perioperative effects and can allow for personalized anesthesia and pain management for improvement of pain control and reduction of anesthesia-, analgesic-, and opioid-related adverse outcomes. These methods and compositions apply to non-surgical pain management with opioids. Therefore, patients who are genetically predisposed to risk of inadequate pain relief and/or serious side effects from anesthesia, analgesics, and/or opioids can be identified and individualized treatment plans developed for implementation by the clinician to improve clinical and economic outcomes. | 2020-10-08 |
20200318195 | Bivalent Nucleic Acid Ligands and Uses Therefor - Genetic recognition reagents comprising bivalent nucleobases are provided that bind two strands of nucleic acid, such as an expanded repeat sequence associated with an expanded repeat disease. In one example the expanded repeat disease is a polyQ disease, such as Huntington's disease. Methods of use of the reagents are provided, including a method of binding nucleic acid, such as an expanded repeat sequence associated with an expanded repeat disease, a method of identifying the presence of a nucleic acid comprising an expanded repeat, and a method of treating an expanded repeat disease are provided. | 2020-10-08 |
20200318196 | USE OF BIOMARKERS IN DETERMINING SUSCEPTIBILITY TO DISEASE TREATMENT - The present invention refers to a method of predicting susceptibility of a subject suffering from cancer to a treatment with an anti-cancer drug, wherein the method comprises detecting the presence or absence of a genetic alteration in a long non-coding RNA (IncRNA) that resides in an antisense strand of an oncogene, wherein the genetic alteration disrupts expression of the oncogene, and wherein the subject is predicted to be more susceptible to the treatment if the genetic alteration is present. In particular, the genetic alteration is a silent G>A mutation at Q787Q of the oncogene epidermal growth factor receptor (EGFR). Also disclosed herein is a method of treating a subject suffering from cancer, who was shown to have a genetic alteration in IncRNA that resides in an antisense strand of an oncogene. | 2020-10-08 |